Newsroom
April 20, 2022
Thanks to international collaboration, more genetic variations for Alzheimer’s disease are known today than ever before. The list of gene variants recognized for late-onset Alzheimer’s grew from one in 2009 to 40 in 2022. This month, scientists published a list of 75, some of which are considered as prime drug targets. Drug development is underway.
February 9, 2022
Treatment could aim to raise levels of a neuroprotective molecule, studies hint. Contact: Will Sansom, (210) 567-2579, sansom@uthscsa.edu SAN ANTONIO (Feb. 9, 2022) — Growing evidence suggests that traumatic brain injury (TBI) is an important risk factor for developing Alzheimer’s disease and dementia. But to date, effective therapies aren’t available for preventing or treating TBI-induced […]
October 19, 2021
Dr. Brian Fricke, Rehabilitation Medicine, is quoted in this story about the recovery process of one of his patients. Watch story
October 19, 2021
Dr. James Lechleiter, Cell Systems and Anatomy, is quoted in this KENS 5 story. Watch story
October 14, 2021
Dr. Sudha Seshadri, Neurology, Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, was a guest on Texas Public Radio’s “The Source” and discussed how UT Health San Antonio and The University of Texas Rio Grande Valley will work together to address the disproportionate impact of Alzheimer’s in Latinos at a new nationally designated Alzheimer’s Disease […]
October 8, 2021
Research that began at The University of Texas Health Science Center at San Antonio 15 years ago is nearing a significant milestone: human testing of an intravenous (IV) drug to treat brain injuries such as concussion and stroke.